| ★ | ZUPREME-1: Petrelintide Reduces Obesity, Maintains Tolerability in Phase 2 Trial | | 81 | Estados Unidos | |
| 14 | Understanding Memory Loss | Stanford Health Care @stanfordhospital | 1.2K | Estados Unidos | 63 |
| 11 | Inside the VESPER-3 Results: Berobenatide's Weight Loss Potential | | 839 | Estados Unidos | 65 |
| 16 | IGCSE Core Practical 3 - Enzymes and pH | Mr Exham Biology @mrexhambio | 401 | Reino Unido | 63 |
| 6 | Furoscix ReadyFlow (Furosemide) and its Impact on HF, CKD Edema Treatment | | 374 | Estados Unidos | 67 |
| 8 | Berobenatide Monthly GLP-1 Injectable Shows Promise for Weight Loss | | 250 | Estados Unidos | 66 |
| 12 | All 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Study | | 168 | Estados Unidos | 65 |
| 18 | AHA Publishes Results of Nationwide Initiative for Lp(a) Education and Awareness | | 161 | Estados Unidos | 63 |
| 10 | Secondary Analyses of OCEANIC-STROKE Confirm Efficacy of Asundexian | | 113 | Estados Unidos | 65 |
| 2 | Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD | | 88 | Estados Unidos | 68 |
| 17 | SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes | | 86 | Estados Unidos | 63 |
| 19 | Addressing Advances and Roadblocks in Lipid Management, With Joseph Saseen, PharmD | | 64 | Estados Unidos | 63 |
| 13 | GP-SOD Plus Targeted Phototherapy for Vitiligo: Safety, Dosing, Next Steps | | 60 | Estados Unidos | 64 |
| 3 | Safety objectives and functions at ITER | UNED Cursos MOOC @unedcursoscoma | 50 | España | 68 |
| 1 | Mifepristone Improves HbA1c, Weight in Poorly Controlled T2D, Regardless of GLP-1 Treatment | | 46 | Estados Unidos | 69 |
| 9 | Metreleptin-Neutralizing Antibodies Do Not Impact Treatment Outcomes in Generalized Lipodystrophy | | 40 | Estados Unidos | 66 |
| 5 | Diagnosing Non-IgE Food Hypersensitivity | Brian Lacy, MD, PhD | EAC 2026 | | 31 | Estados Unidos | 68 |
| 20 | Treadmill Stress Tests Safe, Reliable for Detecting Severe Asymptomatic Aortic Stenosis | | 29 | Estados Unidos | 63 |
| 15 | Brief, Regular Movement Breaks Can Improve Cardiovascular Risk in T2D | | 24 | Estados Unidos | 63 |
| 4 | Abdominal Pain and Bloating: Recognizing HAE, MCAS, and Eosinophilic GI Disorders | Brian Lacy, MD | | 20 | Estados Unidos | 68 |
| 7 | Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D | | 16 | Estados Unidos | 67 |